OTCMKTS:EMMA

Emmaus Life Sciences Competitors

$1.30
0.00 (0.00 %)
(As of 04/16/2021 08:10 PM ET)
Add
Compare
Today's Range
$1.30
Now: $1.30
$1.30
50-Day Range
$1.30
MA: $1.51
$1.71
52-Week Range
$0.70
Now: $1.30
$2.16
Volume500 shs
Average Volume14,258 shs
Market Capitalization$63.68 million
P/E RatioN/A
Dividend YieldN/A
Beta2.34

Competitors

Emmaus Life Sciences (OTCMKTS:EMMA) Vs. CLBS, BXRX, CCEL, GRNV, PFHOD, and CTYX

Should you be buying EMMA stock or one of its competitors? Companies in the industry of "miscellaneous health & allied services, not elsewhere classified" are considered alternatives and competitors to Emmaus Life Sciences, including Caladrius Biosciences (CLBS), Baudax Bio (BXRX), Cryo-Cell International (CCEL), GreenVision Acquisition (GRNV), Pacific Health Care Organization (PFHOD), and Curative Biotechnology (CTYX).

Emmaus Life Sciences (OTCMKTS:EMMA) and Caladrius Biosciences (NASDAQ:CLBS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for Emmaus Life Sciences and Caladrius Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emmaus Life Sciences0000N/A
Caladrius Biosciences01302.75

Caladrius Biosciences has a consensus price target of $10.00, indicating a potential upside of 553.59%. Given Caladrius Biosciences' higher probable upside, analysts plainly believe Caladrius Biosciences is more favorable than Emmaus Life Sciences.

Earnings & Valuation

This table compares Emmaus Life Sciences and Caladrius Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emmaus Life Sciences$1.32 million48.24$-2,370,000.00N/AN/A
Caladrius BiosciencesN/AN/A$-19,360,000.00($1.88)-0.81

Emmaus Life Sciences has higher revenue and earnings than Caladrius Biosciences.

Insider and Institutional Ownership

0.1% of Emmaus Life Sciences shares are held by institutional investors. Comparatively, 9.0% of Caladrius Biosciences shares are held by institutional investors. 36.9% of Emmaus Life Sciences shares are held by company insiders. Comparatively, 10.3% of Caladrius Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Emmaus Life Sciences and Caladrius Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emmaus Life SciencesN/AN/AN/A
Caladrius BiosciencesN/A-68.33%-57.61%

Volatility & Risk

Emmaus Life Sciences has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, Caladrius Biosciences has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.

Summary

Emmaus Life Sciences beats Caladrius Biosciences on 6 of the 9 factors compared between the two stocks.

Emmaus Life Sciences (OTCMKTS:EMMA) and Baudax Bio (NASDAQ:BXRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Emmaus Life Sciences and Baudax Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emmaus Life SciencesN/AN/AN/A
Baudax BioN/AN/AN/A

Valuation and Earnings

This table compares Emmaus Life Sciences and Baudax Bio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emmaus Life Sciences$1.32 million48.24$-2,370,000.00N/AN/A
Baudax BioN/AN/A$-32,560,000.00($3.48)-0.31

Emmaus Life Sciences has higher revenue and earnings than Baudax Bio.

Analyst Recommendations

This is a summary of current ratings for Emmaus Life Sciences and Baudax Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emmaus Life Sciences0000N/A
Baudax Bio00203.00

Baudax Bio has a consensus target price of $13.50, suggesting a potential upside of 1,161.68%. Given Baudax Bio's higher possible upside, analysts clearly believe Baudax Bio is more favorable than Emmaus Life Sciences.

Insider & Institutional Ownership

0.1% of Emmaus Life Sciences shares are held by institutional investors. Comparatively, 7.9% of Baudax Bio shares are held by institutional investors. 36.9% of Emmaus Life Sciences shares are held by company insiders. Comparatively, 13.1% of Baudax Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Emmaus Life Sciences has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, Baudax Bio has a beta of 2.56, indicating that its stock price is 156% more volatile than the S&P 500.

Summary

Baudax Bio beats Emmaus Life Sciences on 4 of the 7 factors compared between the two stocks.

Emmaus Life Sciences (OTCMKTS:EMMA) and Cryo-Cell International (OTCMKTS:CCEL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Volatility & Risk

Emmaus Life Sciences has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500. Comparatively, Cryo-Cell International has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500.

Profitability

This table compares Emmaus Life Sciences and Cryo-Cell International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emmaus Life SciencesN/AN/AN/A
Cryo-Cell International10.39%-58.74%7.30%

Valuation and Earnings

This table compares Emmaus Life Sciences and Cryo-Cell International's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emmaus Life Sciences$1.32 million48.24$-2,370,000.00N/AN/A
Cryo-Cell International$31.80 million2.35$2.29 millionN/AN/A

Cryo-Cell International has higher revenue and earnings than Emmaus Life Sciences.

Analyst Recommendations

This is a summary of current recommendations for Emmaus Life Sciences and Cryo-Cell International, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emmaus Life Sciences0000N/A
Cryo-Cell International0000N/A

Insider and Institutional Ownership

0.1% of Emmaus Life Sciences shares are held by institutional investors. Comparatively, 1.0% of Cryo-Cell International shares are held by institutional investors. 36.9% of Emmaus Life Sciences shares are held by insiders. Comparatively, 53.8% of Cryo-Cell International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Cryo-Cell International beats Emmaus Life Sciences on 6 of the 9 factors compared between the two stocks.

GreenVision Acquisition (NASDAQ:GRNV) and Emmaus Life Sciences (OTCMKTS:EMMA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations and price targets for GreenVision Acquisition and Emmaus Life Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GreenVision Acquisition0000N/A
Emmaus Life Sciences0000N/A

Valuation & Earnings

This table compares GreenVision Acquisition and Emmaus Life Sciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GreenVision AcquisitionN/AN/AN/AN/AN/A
Emmaus Life Sciences$1.32 million48.24$-2,370,000.00N/AN/A

GreenVision Acquisition has higher earnings, but lower revenue than Emmaus Life Sciences.

Insider & Institutional Ownership

67.7% of GreenVision Acquisition shares are held by institutional investors. Comparatively, 0.1% of Emmaus Life Sciences shares are held by institutional investors. 36.9% of Emmaus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares GreenVision Acquisition and Emmaus Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GreenVision AcquisitionN/AN/AN/A
Emmaus Life SciencesN/AN/AN/A

Summary

Emmaus Life Sciences beats GreenVision Acquisition on 2 of the 3 factors compared between the two stocks.

Pacific Health Care Organization (OTCMKTS:PFHOD) and Emmaus Life Sciences (OTCMKTS:EMMA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Insider & Institutional Ownership

0.1% of Emmaus Life Sciences shares are owned by institutional investors. 61.6% of Pacific Health Care Organization shares are owned by company insiders. Comparatively, 36.9% of Emmaus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Pacific Health Care Organization has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Emmaus Life Sciences has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Pacific Health Care Organization and Emmaus Life Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacific Health Care Organization0000N/A
Emmaus Life Sciences0000N/A

Profitability

This table compares Pacific Health Care Organization and Emmaus Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacific Health Care Organization16.87%14.47%12.96%
Emmaus Life SciencesN/AN/AN/A

Valuation & Earnings

This table compares Pacific Health Care Organization and Emmaus Life Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacific Health Care Organization$6.80 million2.35$1.36 millionN/AN/A
Emmaus Life Sciences$1.32 million48.24$-2,370,000.00N/AN/A

Pacific Health Care Organization has higher revenue and earnings than Emmaus Life Sciences.

Summary

Pacific Health Care Organization beats Emmaus Life Sciences on 6 of the 9 factors compared between the two stocks.

Emmaus Life Sciences (OTCMKTS:EMMA) and Curative Biotechnology (OTCMKTS:CTYX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Profitability

This table compares Emmaus Life Sciences and Curative Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emmaus Life SciencesN/AN/AN/A
Curative BiotechnologyN/AN/AN/A

Volatility & Risk

Emmaus Life Sciences has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500. Comparatively, Curative Biotechnology has a beta of -31.94, indicating that its share price is 3,294% less volatile than the S&P 500.

Institutional and Insider Ownership

0.1% of Emmaus Life Sciences shares are owned by institutional investors. 36.9% of Emmaus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Emmaus Life Sciences and Curative Biotechnology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emmaus Life Sciences0000N/A
Curative Biotechnology0000N/A

Valuation and Earnings

This table compares Emmaus Life Sciences and Curative Biotechnology's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emmaus Life Sciences$1.32 million48.24$-2,370,000.00N/AN/A
Curative BiotechnologyN/AN/AN/AN/AN/A

Curative Biotechnology has lower revenue, but higher earnings than Emmaus Life Sciences.

Summary

Emmaus Life Sciences beats Curative Biotechnology on 4 of the 4 factors compared between the two stocks.


Emmaus Life Sciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Caladrius Biosciences logo
CLBS
Caladrius Biosciences
1.5$1.53flat$91.03 millionN/A-2.39Decrease in Short Interest
News Coverage
Baudax Bio logo
BXRX
Baudax Bio
1.4$1.07flat$75.05 millionN/A-0.31Increase in Short Interest
Cryo-Cell International logo
CCEL
Cryo-Cell International
0.9$9.88flat$74.80 million$31.80 million24.70High Trading Volume
Gap Down
GRNV
GreenVision Acquisition
0.3$10.18flat$73.17 millionN/A0.00Increase in Short Interest
PFHOD
Pacific Health Care Organization
0.5$1.25flat$52.48 million$6.80 million0.00Gap Up
CTYX
Curative Biotechnology
0.0$0.12flat$47.20 millionN/A0.00
BRTXQ
BioRestorative Therapies
0.0$0.03flat$16.56 million$110,000.00-0.03High Trading Volume
BioRestorative Therapies logo
BRTX
BioRestorative Therapies
0.6$0.01flat$16.56 million$110,000.000.00Gap Down
PFHO
Pacific Health Care Organization
0.8$1.12flat$14.27 million$7.33 million0.00Gap Up
GNOW
American Caresource
0.7$0.01flat$124,000.00N/A0.00Gap Down
HYBE
Hybrid Energy
0.0$0.00flat$0.00N/A0.00
QMED
QMed
0.2$0.00flat$0.00N/A0.00Gap Up
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.